|
Market Closed -
Nasdaq
16:00:00 2026-09-29 EDT
|
5-day change | 1st Jan Change | ||
| 0.8103 USD | -2.56% |
|
-18.97% | -71.77% |
| 09-23 | Tempest Therapeutics, Inc. Announces Appointment of Nancy Freda-Smith to Its Board of Director and Chair of Audit Committee | CI |
| 09-16 | Top Premarket Gainers | MT |
Company Valuation: Tempest Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 36.49 | 12.09 | 84.69 | 36.42 | 14.14 | 13.3 | - | - |
| Change | - | -66.85% | 600.22% | -57% | -61.17% | -5.94% | - | - |
| Enterprise Value (EV) | 36.49 | 12.09 | 84.69 | 36.42 | 14.14 | 13.3 | 13.3 | 13.3 |
| Change | - | -66.85% | 600.22% | -57% | -61.17% | -5.94% | 0% | 0% |
| P/E | - | -0.37x | -2.3x | -0.56x | -0.45x | -0.28x | -0.9x | 0.27x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | - | 0.1x | 0x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 3.09x |
| EV / Revenue | - | - | - | - | - | - | - | 3.09x |
| EV / EBITDA | -0x | -0x | -0x | - | -0x | -0.65x | -0.6x | -0.62x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.65x | -0.6x | -0.62x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | -40.17 | -24.83 | -19.5 | -6.33 | -2.85 | -0.9 | 3 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 4.3 |
| EBITDA 1 | -26.99 | -34.64 | -28.78 | - | -26.31 | -20.5 | -22.2 | -21.6 |
| EBIT 1 | -26.99 | -34.64 | -29.16 | -42.03 | -26.58 | -20.5 | -22.2 | -21.6 |
| Net income 1 | - | -35.71 | -29.49 | -41.84 | -26.26 | -19.9 | -21.9 | -21.3 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 68.6400 | 14.9500 | 57.2000 | 10.8485 | 2.8700 | 0.8103 | 0.8103 | 0.8103 |
| Nbr of stocks (in thousands) | 532 | 809 | 1,481 | 3,357 | 4,927 | 16,540 | - | - |
| Announcement Date | 3/29/22 | 3/22/23 | 3/19/24 | 3/27/25 | 3/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.29x | - | - | - | 13.75M | |
| 34.14x | 6.12x | 18.32x | 0.95% | 49.06B | |
| 34.9x | 3.36x | 14.48x | -.--% | 44.6B | |
| -20.74x | 225.54x | -22.4x | -.--% | 43.24B | |
| 48.07x | 5.56x | 30.53x | -.--% | 41.73B | |
| 26.98x | 7.78x | 20.03x | 0.42% | 29.93B | |
| 35.03x | 5.75x | 26.11x | -.--% | 17.19B | |
| -61.09x | 9.99x | 243.97x | -.--% | 15.35B | |
| 26.24x | 2.25x | 9.73x | 1.02% | 15.54B | |
| Average | 13.69x | 33.29x | 42.60x | 0.3% | 28.52B | |
| Weighted average by Cap. | 20.34x | 42.68x | 26.48x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TPST Stock
- Valuation Tempest Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
